News

Eight fundraising heroes, one aim: to raise funds for the Cancer Treatment and Research Trust On Sunday April 26th, eight amazing CTRT supporters joined over 59,000 other runners to complete the 46th TCS London Marathon. In doing so, Fabius, Hannah, Scott, Ellie, Reece, Ryan, Gemma and James raised an astounding £42,000 and counting for the Cancer Treatment and Research Trust, the biggest amount we have raised for an event as a charity. The money raised will help us in our mission to improve lives through research and to help patients live longer, improve their quality of life, and better manage their treatment. It was an historic day - attracting a record-breaking number of participants (59, 830) and breaking the world record for the biggest annual one-day fundraising event (£87.5 million and still counting!). A new world record was also set by Sabastian Sawe who became the first athlete to break the two-hour barrier in an official competition! Each of our eight superstars had their own, personal reason and motivation for taking on the challenge: Fabius ran to honour his mother Jasma, a survivor of Stage 4 brain, lung and womb cancer Hannah who was diagnosed with Gestational Trophoblastic Disease (GTD) in 2022 and recovered under our care, ran her first marathon to raise money for our GTD research trial Ellie completed the marathon in loving memory of her best friend who she lost to cancer two years ago James ran to honour his wife who was diagnosed with Gestational Trophoblastic Disease (GTD) and was treated at Charing Cross Hospital Ryan dedicated his run to his dad who was diagnosed with skin cancer and treated at Mount Vernon Cancer Centre Scott completed the marathon to honour his dad who has been battling skin cancer since 2017 Reece dedicated his run to his sister who was diagnosed with Gestational Trophoblastic Disease (GTD) and treated at Charing Cross Hospital Gemma ran to honour her dad who survived cancer of the salivary gland and skin cancer Their shared goal, however — to support CTRT — will ensure that the impact of their arduous training, fantastic fundraising and successful completion of the London Marathon will extend way beyond the finish line. The vital funds raised by our incredible Team CTRT will be used to research why and how cancers develop, find better ways of detecting and monitoring cancers, and test new treatments particularly for rare cancers that don’t receive funding elsewhere. If you’re feeling motivated by reading this, why not take a look at our Challenge Events page to find opportunities to push your limits or simply have fun to support our cause? Your participation can make a real difference. Challenge Events - The Cancer Treatment and Research Trust Interested in joining Team CTRT in future London Marathon races? You can find more information here (The London Marathon - The Cancer Treatment and Research Trust) on how to take part.

Gestational trophoblastic disease (GTD) comprises a rare group of pregnancy-related tumours, ranging from premalignant forms, including partial and complete hydatidiform moles (molar pregnancies), to malignant types (referred to as gestational trophoblastic neoplasia (GTN)), which include invasive mole, choriocarcinoma, placental site trophoblastic tumours and epithelioid trophoblastic tumours. Although uncommon, GTD affects around 220,000 women globally each year, with 22,000 developing GTN. In a recent podcast, the Editor-in-Chief of the International Journal of Gynecological Cancer, Dr Pedro Ramirez, sat down with CTRT’s Chair of Trustee’s Professor Michael Seckl and Dr Christianne Lok, two leading international experts in gynaecologic oncology, to discuss Practical Guidelines for the Treatment of GTD: Collaboration of the European Organization for the Treatment of Trophoblastic Disease (EOTTD)-European Society of Gynecologic Oncology (ESGO)-Gynecologic Cancer Intergroup (GCIG)-International Society for the Study of Trophoblastic Diseases (ISSTD), recently published in the Journal of Clinical Oncology. Developed by 53 specialists across 31 countries, these guidelines represent the most comprehensive global consensus to date. One key topic of discussion in the podcast was the importance of specialized GTD centres. The new guidelines define clear criteria for such centres, with the hope of improving access to expert care worldwide. Even though these tumours are uncommon, centralization of care, the experts explained, improves outcome, as shown in studies of other cancers and rare diseases. The experts also emphasized that careful history-taking should always be part of the diagnostic process, regardless of any latest developments. Abnormal bleeding, severe nausea or abdominal pain can point to GTD, but confirmation relies on ultrasonography, measurement of human chorionic gonadotropin (hCG; a pregnancy hormone often raised in GTD), and most importantly, tissue analysis; genetic testing can also help. The guidelines also include flowcharts to guide doctors through diagnostic dilemmas. Another focus of the guidelines is treatment approaches. For low-risk GTN, single-agent chemotherapy with either methotrexate or actinomycin D is highly effective; the choice of drug often depends on local healthcare systems and patient preference. For high- and ultra-high-risk patients, low-dose induction regimens are often advised prior to more intensive combination chemotherapy treatment to avoid dangerous complications. The experts highlighted how immunotherapy has emerged as a transformative treatment option, particularly for patients who previously faced poor outcomes, as well as offering new hope for patients with very rare subtypes such as placental site and epithelioid trophoblastic tumours. Finally, the guidelines emphasize individualized follow-up. The accompanying flowcharts help clinicians tailor surveillance, while recent evidence has suggested that follow-up after partial and complete moles could potentially be shortened once hCG levels normalize — welcome news for women hoping to conceive again. The experts also considered fertility in their discussion of disease recurrence in the podcast. These new guidelines represent a milestone for GTD care, paving the way for better support and outcomes for patients worldwide. Listen to the full podcast with Professor Seckl and Dr Lok here.